Elizabeth Parrish is a researcher in the field of gene therapy. Her published work investigates gene therapy approaches for healthy life extension, including intranasal and injectable methods, as well as the assessment of biosimilar gene therapies.
22 claims checked on air: 2 context 1 contradicted 4 overstated 8 supported 7 unverified
"Telomerase reverse transcriptase is not shared outside the cell. So, we needed to hit as many of the cells as we possibly could" (said at 0:00:15)
No published record matching the claim that telomerase reverse transcriptase (TERT) protein is not shared outside the cell was located; this does not prove the claim false.
"And this takes us back to 1960 when we finally encouraged the US government to consider cancer a disease. As you know, it wasn't considered a disease. It was considered a consequence of aging." (said at 0:07:01)
Historical and legislative records contradict the claim that the US government did not consider cancer a disease until 1960. The US federal government formally recognized cancer as a disease and a major public health priority decades earlier. In 1937, President Franklin D. Roosevelt signed the National Cancer Institute Act into law, creating the National Cancer Institute (NCI) within the Public Health Service to conduct and support research into the causes, diagnosis, and treatment of cancer. Furthermore, in 1955, the federal government established the Cancer Chemotherapy National Service Center to organize a national effort for developing cancer therapeutics.
"It was, however, four World War II-related programs, and the effects of drugs that evolved from them, that provided the impetus to establish in 1955 the national drug development effort known as the Cancer Chemotherapy National Service Center." (abstract, passage verified)openalexfull study (doi)
"On August 5, 1937, President Franklin Delano Roosevelt signed into law the National Cancer Institute Act, and two months later ground was broken for the NCI building." (abstract, passage verified)openalexfull study (doi)
"In 24 species, including humans, lifespans are tied to that shortening." (said at 0:10:05)
Comparative studies examining telomere dynamics across diverse animal species and humans have shown that the rate of telomere shortening, rather than initial telomere length alone, strongly correlates with species lifespan. For example, Whittemore et al. (2019) measured longitudinal telomere shortening rates across various bird and mammalian species alongside human data, concluding that telomere shortening rate predicts species maximum lifespan. The claim captures the core scientific finding that species longevity correlates with telomere shortening rates, though the exact number of species and the causal universality across all taxa remain subjects of ongoing debate in evolutionary biology.
"We found that the telomere shortening rate, but not the initial telomere length alone, is a powerful predictor of species life span. These results support the notion that critical telomere shortening and the consequent onset of telomeric DNA damage and cellular senescence are a general determinant of species life span." (abstract, results, passage verified)pubmedfull study (doi)
"the diseases of aging that you are diagnosed with come when they're at about 5,000 base pairs. Your cells then go senescent so they no longer divide." (said at 0:10:18)
While in vitro studies of human somatic cells show that replicative senescence (permanent cessation of cell division) occurs after progressive telomere loss when mean terminal restriction fragment lengths reach critical thresholds (often cited in the range of 4 to 6 kilobases, or ~5,000 base pairs), clinical diseases of aging are multifactorial. Although short leukocyte telomere length correlates with increased risk for various age-related diseases, there is no universal threshold of 5,000 base pairs at which clinical diseases are diagnosed, and individual chromosome ends can trigger DNA damage responses and senescence before mean telomere length reaches a fixed numerical cutoff.
"Mammalian telomeres might have 1-50 kb of telomeric DNA, which becomes 40-200 base pairs shorter after per cell cycle, and becomes 5-8 kilobase shorter during senescence. There are many studies on the correlation of telomere length and aging rate... Some of the age related diseases may develop due to telomere dysfunction and telomere shortness. The short telomere structure detected in both peripheral blood leukocytes and cells of the disease-related tissue has the feature of being a predictive marker for many age-related diseases." (abstract, passage verified)pubmedfull study (doi)
"Replicative capacity was found to be directly proportional to mean TRF length (m = 7.2 population doublings/kbp, r = 0.65, P = 0.0004) and total signal intensity (m = 25.0 population doublings/unit, r = 0.63, P < 0.003) at early passage... our observations support the existence of a critical telomere length in senescing cells and a causal role of telomere shortening in cell senescence." (abstract, results, passage verified)pubmedfull study (doi)
"So they have a LMNA gene defect. It creates more progerin in the cell and it degrades the telomeres at the ends of the chromosomes." (said at 0:10:34)
The speaker's statement accurately summarizes the core genetic and cellular mechanism of Hutchinson-Gilford progeria syndrome (HGPS). HGPS is caused by a mutation in the LMNA gene that activates an abnormal splice site, leading to the accumulation of a mutant, truncated lamin A protein called progerin. Progerin disrupts nuclear architecture and genome stability, directly leading to accelerated telomere shortening and telomere dysfunction at chromosome ends.
"This review focuses on one of the most severe laminopathies, Hutchinson-Gilford Progeria Syndrome (HGPS), which is caused by aberrant splicing of the LMNA gene and expression of a mutant product called progerin. Here, we discuss current views about the molecular mechanisms that contribute to the pathophysiology of this devastating disease... In particular, progerin accumulation elicits nuclear morphological abnormalities, misregulated gene expression, defects in DNA repair, telomere shortening, and genomic instability, all of which limit cellular proliferative capacity." (abstract, passage verified)pubmedfull study (doi)
"HGPS is an immensely uncommon, deadly, metameric ill-timed laminopathies caused by the abnormal splicing of the LMNA gene and production of an aberrant protein known as progerin... Due to the production of progerin, an abnormal protein leads to an abnormality in nuclear structure, defects in DNA repair, shortening of telomere, and impairment in gene regulation which ultimately results in aging in the early stage of life." (abstract)pubmedfull study (doi)
"There are genes like follistatin that you could put here and here in your arms, and they actually share the protein throughout your blood system. So the protein goes into your blood, it blocks myostatin, and has a myriad of benefits of lowering inflammatory markers and other things." (said at 0:15:00)
Preclinical and early translational studies confirm the mechanism described: intramuscular delivery of follistatin gene constructs (e.g., AAV-FS344) results in muscle production and secretion of follistatin into the systemic circulation (serum), where it acts as a potent antagonist to myostatin. Additionally, animal models of obesity and joint disease demonstrate that AAV-mediated follistatin gene therapy reduces systemic inflammatory cytokines and adipokines. However, evidence regarding systemic anti-inflammatory benefits remains largely confined to animal models.
"In this review we demonstrate a strategy to bypass off-target effects using an alternatively spliced cDNA of follistatin (FS344) delivered by adeno-associated virus (AAV) to muscle. The transgene product is a peptide of 315 amino acids that is secreted from the muscle and circulates in the serum, thus avoiding cell-surface binding sites." (abstract, results, passage verified)pubmedfull study (doi)
"Follistatin (FST), a protein that binds myostatin and activin, may have the potential to enhance muscle formation while inhibiting inflammation. Here, we hypothesized that adeno-associated virus 9 (AAV9) delivery of FST enhances muscle formation and mitigates metabolic inflammation and knee OA caused by a high-fat diet in mice. AAV-mediated FST delivery exhibited decreased obesity-induced inflammatory adipokines and cytokines systemically and in the joint synovial fluid." (abstract, results, passage verified)pubmedfull study (doi)
"36 million people will die this year of biological aging." (said at 0:20:43)
No published record matching the claim that approximately 36 million people die globally each year from biological aging was located; this does not prove the claim false.
"As we saw in COVID, immune senescence, meaning short telomeres in your immune system, was a lethal cause of death in that condition. And so when they tested people's telomeres in their T lymphocytes after death, they all had exhausted immune systems." (said at 0:22:50)
Observational studies and theoretical models show that shorter telomere length in peripheral blood lymphocytes or leukocytes is associated with increased severity and mortality risk in COVID-19 patients, and autopsy lung tissue from COVID-19 non-survivors showed signs of cellular senescence. However, the speaker overstates this by claiming that short telomeres in T lymphocytes were a definitive "lethal cause of death" and that post-mortem testing showed "they all had exhausted immune systems." In published studies, shorter telomeres are a risk factor and correlation rather than an established singular cause of death, and post-mortem analyses have examined small autopsy cohorts demonstrating senescence markers in lung tissue rather than a universal finding of complete immune exhaustion across all deceased patients.
"Short telomeres were associated with a higher risk of critical disease, defined as admission to intensive care unit (ICU) or death without ICU. TL was negatively correlated with C-reactive protein and neutrophil-to-lymphocyte ratio. Finally, lung tissue from patients with very short telomeres exhibit signs of senescence in structural and immune cells. Our results suggest that TL influences the severity of the disease." (abstract, results, passage verified)pubmedfull study (doi)
"We find that shorter telomeres are associated to increased severity of the disease. Individuals within the lower percentiles of telomere length and higher percentiles of short telomeres have higher risk of developing severe COVID-19 pathologies." (abstract, results, passage verified)pubmedfull study (doi)
"The collapse in the T-cell clonal expansion capacity coincides with the steep increase in COVID-19 mortality with age. Short HCTL might increase vulnerability of many older adults, and some younger individuals with inherently short HCTL, to COVID-19 T-cell lymphopenia and severe disease." (abstract, results, passage verified)pubmedfull study (doi)
"Neurocognitive—we released a paper years ago that was the first dementia study with gene therapy in the entire world, where we used Klotho and telomerase reverse transcriptase to see improved cognition in those patients. And this tiny amount of TERT actually made their immune system telomeres longer." (said at 0:23:18)
No published record matching a clinical study administering dual Klotho and TERT gene therapy to dementia patients that resulted in lengthened immune system telomeres and improved cognitive scores was located; this does not prove the claim false.
"it's directed intranasal delivery with needles. Um because um AAV doesn't transfect well through the the mucosa." (said at 0:27:44)
Preclinical and in vitro studies on human airway and nasal epithelial tissues demonstrate that adeno-associated virus (AAV) vectors (specifically standard serotypes such as AAV-2) transduce intact apical mucosal surfaces very poorly. The mucosal barrier, absence of accessible apical receptors, and rapid endosomal/proteasomal degradation significantly restrict gene transfer across the intact airway and nasal mucosa compared to basolateral delivery or direct tissue injection.
"The restriction of viral receptors and coreceptors to the basolateral surface of airway epithelial cells has been blamed for the inefficient transfer of viral vectors to the apical surface of this tissue... The dramatically lower transduction efficiency of rAAV infection from the apical surface of airway cells appears to result instead from differences in endosomal processing and nuclear trafficking of apically or basolaterally internalized virions." (abstract, results, passage verified)pubmedfull study (doi)
"In contrast, rAAV-2 has been shown to be inherently ineffective at transducing airway epithelia from the apical surface." (abstract, results, passage verified)pubmedfull study (doi)
"Upon autopsy, patients who had all of the signs of Alzheimer's, uh, the beta-amyloid plaques and and the shrinkage of the brain, who didn't have cognitive issues, did not show the cognitive symptoms of the disease, were all natural alpha-Klotho upregulators." (said at 0:30:51)
No published record matching the claim that an autopsy study found individuals with severe Alzheimer's neuropathology who remained cognitively intact were all natural upregulators of alpha-Klotho was located; this does not prove the claim false. While the KLOTHO longevity gene and the KL-VS heterozygote variant have been investigated for potential neuroprotective associations against cognitive decline and Alzheimer's biomarkers in living cohorts, no autopsy study establishing universal alpha-Klotho upregulation in asymptomatic individuals with full Alzheimer's pathology was identified.
"When we looked at telomerase reverse transcriptase, we looked at the the research behind it. It actually seems to have a reparative effect on mitochondria in the same cell by reducing oxidative stress. Now that there is a complete feedback loop between mitochondria and longer telomeres and so it it had been shown in research um this feedback loop." (said at 0:34:20)
Research in cell models and animal studies demonstrates that telomerase reverse transcriptase (TERT) localizes to mitochondria, where it protects mitochondrial DNA and reduces mitochondrial reactive oxygen species (ROS) and oxidative stress. Furthermore, literature establishes a functional reciprocal link (mitochondria-telomere axis) where mitochondrial dysfunction and ROS promote telomere erosion, while TERT expression and mitochondrial localization protect mitochondrial function and maintain cellular homeostasis.
"Mitochondrial TERT exerts a novel protective function by binding to mitochondrial DNA, increasing respiratory chain activity and protecting against oxidative stress-induced damage." (abstract, conclusions, passage verified)pubmedfull study (doi)
"This study also shows that activation of the peroxisome proliferator-activated receptor- γ coactivator-1 α (PGC-1 α )/telomerase reverse transcriptase (TERT) pathway, which is the new link between mitochondria and telomere, was involved in the protective effects of catalpol." (abstract, results, passage verified)pubmedfull study (doi)
"Our results suggest a protective function of TERT against OS, also preserving mitochondrial functionality." (abstract, conclusions, passage verified)pubmedfull study (doi)
"Also lengthening the telomeres created less tau tangles in neurons and so we're excited about that." (said at 0:34:50)
Preclinical models demonstrate that telomere attrition and telomere-driven cellular senescence accelerate tau hyperphosphorylation, truncation, and neurofibrillary aggregation in tauopathy mouse models. However, stating definitively that lengthening telomeres reduces tau tangles in neurons overstates the current evidence, which is confined to preliminary animal and cellular studies rather than established human clinical trials.
"Additionally, we found evidence that the introduction of a senescent phenotype in a tauopathy mouse model results in increased tau phosphorylation at key residues, particularly in the hippocampus. Over time, this leads to enhanced tau truncation and aggregation, accompanied by exacerbated astrocyte and microglial activation, as well as selective neuronal loss in vulnerable brain regions." (abstract, results, passage verified)pubmedfull study (doi)
"Alpha-Klotho was associated with less beta-amyloid plaques." (said at 0:34:57)
Preclinical animal and cellular models demonstrate that increased expression or lentiviral-mediated overexpression of alpha-Klotho in the brain is associated with reduced amyloid-beta (Aβ) burden and enhanced clearance of Aβ plaques, alongside improved cognitive outcomes in Alzheimer's disease mouse models (such as APP/PS1 mice). Because the direct evidence demonstrating reduced plaque deposition following altered Klotho expression comes primarily from animal and in vitro models, human clinical certainty remains very low.
"These results suggest that the upregulation of Klotho expression in the brain may promote the autophagic clearance of amyloid beta and protect against cognitive deficits in AD mice." (abstract, results, passage verified)pubmedfull study (doi)
"The upregulation of Klotho levels in the brain and serum significantly ameliorated Aβ burden, neuronal and synaptic loss and cognitive deficits in aged APP/PS1 mice." (abstract, results, passage verified)pubmedfull study (doi)
"The α-klotho protein may protect against cognitive decline through multiple mechanisms: such as promoting optimal synaptic function via activation of N-methyl-d-aspartate (NMDA) receptor signalling; stimulating the antioxidant defence system; reducing inflammation; promoting autophagy and enhancing clearance of amyloid-β." (abstract, passage verified)pubmedfull study (doi)
"So yes, it's it's it's associated with uh mitochondrial biogenesis turning white fat to brown fat with this excessive amount of little mitochondria that that darken the stain." (said at 0:35:30)
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is well established as a master transcriptional coactivator of mitochondrial biogenesis and thermogenic gene expression. Activation of PGC-1α drives the recruitment of nuclear respiratory factors and mitochondrial transcription factors, increasing mitochondrial density and oxidative capacity. In white adipose tissue, this process promotes the "browning" (or beigeing) of adipocytes, characterized by dense, iron-rich mitochondria that give brown and beige fat tissue its darker color and thermogenic phenotype.
"Among emerging research areas, fat browning-the transformation of white adipose tissue into beige fat-has gained significant attention. This review explores the molecular pathways involved in fat browning triggered by fasting, physical exercise, and cold exposure, emphasizing both shared and distinct regulatory mechanisms. These stimuli consistently induce physiological responses such as lipolysis, mitochondrial biogenesis, and improved insulin sensitivity. Notably, PGC-1α and SIRT3 are upregulated across all three conditions, underscoring their central roles in mitochondrial function and energy metabolism" (abstract, results, passage verified)pubmedfull study (doi)
"Initially identified in brown adipose tissue in response to cold exposure, PGC-1α regulates cell differentiation by modulating gene expression networks involved in mitochondrial biogenesis. PGC-1α influences cell fate in several cell types, including adipocytes, skeletal muscle cells, and bone marrow-derived cells." (abstract, results, passage verified)pubmedfull study (doi)
"Peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) is a master transcriptional coactivator responsible for regulating cellular energy metabolism and mitochondrial biogenesis across high-energy tissues such as the heart, skeletal muscle, and brown adipose tissue." (abstract, results, passage verified)pubmedfull study (doi)
"adenovirus which is a large virus and and it is the one that kind of shut down gene therapy in in 1990 due to an ill effect." (said at 0:39:44)
The claim is partially accurate regarding the cause and impact of the adverse event, but contains a significant error regarding the date. The landmark adenovirus gene therapy trial that caused severe immunotoxicity, resulted in a high-profile patient death, and halted/slowed clinical gene therapy research occurred in September 1999 (the trial for ornithine transcarbamylase deficiency led by the University of Pennsylvania, in which 18-year-old Jesse Gelsinger died), not in 1990. In 1990, the first approved human gene therapy trial took place (using a retroviral vector for adenosine deaminase deficiency in a four-year-old patient), which was successful and safe.
"It has been 9 years since Mr. Jesse Gelsinger died from complications of vector administration in a liver gene therapy trial of research subjects with a deficiency of ornithine transcarbamylase (OTCD). This study was performed at the Institute for Human Gene Therapy of the University of Pennsylvania (Penn) which I directed. His tragic death provoked a series of events that had implications beyond those directly involved in the clinical trial." (abstract, passage verified)openalexfull study (doi)
"The the reason that people love adeno-associated virus is it vastly 90 some percent of the cases creates what's called an episome. So it means it doesn't integrate into the human chromosome" (said at 0:41:26)
Recombinant adeno-associated virus (rAAV) vectors engineered for gene therapy lack the Rep protein required for targeted genomic integration, causing the vector DNA to remain predominantly (>90–99%) extrachromosomal as circular or concatemeric episomes. While chromosomal integration can still occur at very low frequencies (often estimated at under 1% to a few percent of transduction events), the vast majority of rAAV genomes persist episomally in the nucleus.
"Random integration of vector sequences has been demonstrated in established cell lines but only in some cases and at low frequency in primary cultures and in vivo. In contrast, episomal concatemers predominate." (abstract, passage verified)pubmedfull study (doi)
"Once inside the nucleus, the rAAV genome exists in a predominantly episomal form; therefore, nondividing cells tend to be most stably transduced. However, rAAV has a low frequency of integration into the host cell genome" (abstract, passage verified)pubmedfull study (doi)
"Although most rAAV DNA typically remains episomal, some rAAV DNA becomes integrated into genomic DNA at a low frequency" (abstract, passage verified)pubmedfull study (doi)
"follistatin it's turned out since uh I did that in 2015 is actually involved in a myriad of different biological processes including brain plasticity and that was not known reducing TGF-beta inflammatory markers that was not known. Um it's believed to be protective against both breast and prostate cancer." (said at 0:45:22)
Follistatin (FST) is well-characterized as an antagonist of TGF-beta/activin superfamily signaling pathways. Observational and cell-line research indicates that low follistatin expression correlates with poorer clinical outcomes in specific breast cancer subtypes (such as triple-negative breast cancer), and knockdown of FST increases tumor cell proliferation and invasion in vitro. However, describing follistatin as globally protective against breast and prostate cancers overstates the existing evidence, as its roles are complex, context-dependent, and primarily supported by preclinical models and retrospective tissue databases rather than established clinical preventive effects.
"Adding to the complexity of activin signaling, follistatin, a highly glycosylated monomeric protein, binds activin with high affinity and restrains downstream pathway activation but through a mechanism distinct from that of inhibin." (abstract, passage verified)pubmedfull study (doi)
"Data from TCGA showed that low FST expression correlated with poor prognosis (for univariate analysis, HR = 0.47, 95% CI: 0.27-0.82, p = 0.008; for multivariate analysis, HR = 0.40, 95% CI: 0.21-0.75, p = 0.004)." (abstract, results, passage verified)pubmedfull study (doi)
"we had a patient who was on the um donor list uh on the list to get a donation of a kidney uh and had to and immediately needed one and he took the gene therapy directly image-guided gene therapy to the kidney. He came off the list for two years" (said at 0:50:20)
No published record matching a chronic kidney disease patient receiving image-guided Klotho gene therapy directly to the kidney and coming off a transplant donor list was located; this does not prove the claim false. While preclinical animal models and in vitro studies have investigated Klotho delivery for kidney injury and fibrosis, no published clinical trials or peer-reviewed case reports document this human clinical outcome.
"Because today 110,000 people will die of biological aging" (said at 0:54:20)
No published record matching the claim that approximately 110,000 people die every day from biological aging was located; this does not prove the claim false.
"there's 12 agreed-upon hallmarks of aging." (said at 0:57:00)
The widely recognized scientific framework for aging biology, updated by López-Otín and colleagues in Cell (2023), defines twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. This expanded upon the original nine hallmarks established in 2013.
"We propose the following twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis." (abstract, passage verified)pubmedfull study (doi)
"And in 2024, we worked really hard and the Bahamas passed a law to do such things. And they will be running clinical trials, as as you would expect, to get these drugs into the US FDA regulatory system." (said at 1:01:53)
No published record matching the claim that the Bahamas passed a law in 2024 allowing clinical trials using gene therapy to treat biological aging was located; this does not prove the claim false.